Meningococcal Vaccines Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Meningococcal Conjugate Vaccines, Meningococcal Polysaccharide Vaccine, Serogroup B Meningococcal Vaccine), By End user (Hospitals, Clinic, Others) and By Region Forecast 2020-2031

Meningococcal Vaccine Market size was valued at US$ 6.0 billion in 2024 and is expected to reach US$ 9.1 billion by 2031, growing at a significant CAGR of 6% from 2025-2031. Meningococcal disease is a fatal disease caused by Neisseria Meningitides, which causes potential infection in the meninges, the thin layers of connective tissues surrounding the spinal cord and brain. Common symptoms are bacteremia, pneumonia, and meningitis associated with neck stiffness, nausea, high fever, vomiting, confusion, rashes, and lethargy. The surge in the incidence of meningococcal disease is expected to play a vital role in growth of the global market. Meningococcal meningitis is a major public health concern. Various treatment approaches with reasonable costs have been established, however they continue to result in a high fatality rate. In newborns and young children, they can have long-term neurological repercussions.

According to a WHO estimate, 50 percent of meningitis cases occur in children under the age of five. The next susceptible age group is 15-19 years. Meningitis has negatively impacted humanity, so various multinational private agencies have stepped up to create a vaccine. Meningococcal vaccines are available in four different categories. Meningitis A (MenA) and three Conjugate MenACWY vaccines are available. Furthermore, growing awareness among the people regarding the seriousness of the disease, government initiatives, increased R&D investments by various players, and introduction of advanced vaccines are expected to boost the growth of the meningococcal vaccines market. However, lack of awareness, the high cost of vaccines, unfavourable regulatory conditions are restraining of global market.